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Educational aims
•	 To better appreciate the importance of coronary artery disease in the female 
population
•	 To shed light on the complex effect of oestrogen on the cardiovascular system
•	 To highlight the importance of non-invasive testing in women at intermediate risk for 
ischaemic heart disease
•	 To identify gender differences in medical and interventional management of acute 
coronary syndrome
Abstract
Up to some decades ago, coronary artery disease (CAD) has been 
thought of as being a predominantly ‘male disease’.  Population 
studies have however shown, that CAD is the major cause of death in 
females, surpassing six-fold the death rate due to breast carcinoma.  
Post-menopausally, ischaemic heart disease (IHD) in women is as 
common as in males of the same age group. Hence, the investigation 
and management of females with CAD is vital, in order to decrease the 
mortality in the female population. 
Introduction
The importance of CAD in women has been 
underestimated for many years.1 Currently, IHD 
is responsible for the death of approximately 
400,000 women annually in the US alone, 
making CAD the leading cause of death in 
females.2   There are fundamental differences 
between male and female hearts with regard 
to electrophysiology, contractility, signalling, 
metabolism, and cardioprotection. Differences 
in cardiomyocytes likely contribute to the 
differences in male and female physiology and 
response to disease.3 Pre-menopausal women 
have less cardiovascular disease compared to 
men, yet the incidence of IHD in females rises 
after menopause.
Pathophysiology of CAD in women
Studies investigating sex-related differences 
in the cardiovascular system were lacking 
up to some years ago, but fortunately the 
number of clinical and experimental studies 
has grown exponentially over the past 20 
years. These studies have shown that the 
onset of IHD occurs approximately 10 years 
later in women than in men, with myocardial 
infarction occurring around 20 years later.4 
The incidence of CAD increases dramatically 
in post-menopausal women, suggesting that 
the decline in oestrogen levels may be a major 
contributing factor to this increase. Oestrogen 
has a number of effects on cardiovascular 
function and disease: it modulates vascular 
function and the inflammatory response, 
it affects metabolism, insulin sensitivity 
and calcium handling in cardiac myocytes, 
it influences stem cell survival and the 
development of left ventricular hypertrophy.5   
The exact underlying molecular and cellular 
mechanisms by which oestrogen exerts its 
cardioprotective effects on myocytes, are 
still largely unknown, but it is speculated 
that oestrogen may affect gene and protein 
expression and may modify post-translational 
proteins.3 One would assume that hormone 
replacement therapy (HRT) would decrease 
the incidence of CAD in women.  However 
data is unclear, with groups suggesting the 
‘Therapeutic Window’ theory, reinforcing the 
complex role of oestrogen on cardiac function. 
6,7,8
The Women’s Ischaemia Evaluation (WISE) 
trial and other studies have shed further light 
on the complex pathophysiology of coronary 
atherosclerosis in females which includes 
abnormal coronary reactivity, microvascular 
dysfunction and plaque erosion with distal 
microembolisation.9 Obstetric complications 
such as pre-eclampsia, gestational diabetes 
and pregnancy-induced hypertension, are 
early indicators of cardiovascular risk.10 
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Women are generally older than men when 
they develop IHD and have multiple co-
morbidities. Hypertension, diabetes mellitus 
and renal impairment are more frequent 
among females. After menopause, the level 
of low-density lipoprotein (LDL)-cholesterol 
increases whilst the level of high-density 
lipoprotein (HDL)-cholesterol decreases.11 All 
these factors contribute to a high incidence 
of CAD, especially in post-menopausal women. 
Higher rates of hypertension, left ventricular 
hypertrophy, and diabetes in women, are 
hypothesized to result in a greater degree 
of microvascular rather than macrovascular  
disease. 12
Symptoms of CAD
Numerous observational studies have suggested 
that symptoms of myocardial ischaemia differ 
in the two sexes.  Women were more likely 
to present with angina at the onset of IHD, 
whereas men often present with an acute 
myocardial infarction (AMI) or sudden cardiac 
death. An objective study performed by Mackay 
et al, involved performing percutaneous 
coronary intervention (PCI) in a cohort of 
male and female patients with CAD. Ischaemic 
symptoms were assessed during prolonged 
balloon inflation. No statistical significant 
difference was seen in the frequency of 
ischaemia-induced chest discomfort among 
women versus men. However, females were 
significantly more likely to report throat, jaw 
and neck discomfort.13 On the other hand, 
females experiencing an AMI, are more likely 
to have atypical symptoms such as shortness of 
breath, abdominal, neck, or shoulder pain, or 
nausea and vomiting. 14
Exercise stress testing in women 
Exercise stress testing (EST) is one of the most 
commonly used method of investigating for 
CAD in women and is the initial non-invasive 
test of choice in women with a moderate to 
high pre-test probability of having CHD. EST 
however is known to be less sensitive and less 
specific in the female population resulting in a 
number of false positive results.15   Differences 
in the accuracy of ST-segment depression for 
men and women may be explained by several 
factors. Women are more likely than men to 
have baseline ST-T wave changes, making 
interpretation of ECG changes during exercise 
difficult.16   It has also been hypothesised that 
oestrogen (natural or otherwise), may cause a 
digoxin-like effect on the ST segments during 
exercise. In premenopausal women with no 
CAD, ST depressions during exercise appear to 
vary with the menstrual cycle. 17
Despite this, the American College of 
Cardiology/American Heart Association and 
European Society of Cardiology guidelines, 
still recommend EST as the first line test 
for symptomatic women, who are deemed 
at intermediate risk for IHD and who have 
a normal baseline ECG and are capable of 
performing maximal exercise. 18,19   The 
diagnostic and prognostic accuracy of 
EST in women can be improved by 
incorporating parameters such as exercise 
capacity, chronotropic response, heart 
rate recovery, blood pressure response and 
Duke treadmill score, in addition to ST 
depression during exercise.20 The duration 
of metabolic equivalents  (METS) is the 
strongest prognostic variable with a higher 
death rate in women who can achieve less 
than 5 METs.21 Stress echocardiography, 
and myocardial perfusion imaging further 
contribute to the diagnosis of IHD in women. 
CT coronary angiography is another non-
invasive tool used to assess for obstructive 
CAD in women, with a similar diagnostic 
sensitivity and specificity in both genders.22
Gender differences in the 
management of CAD
Female patients with CAD tend to be older 
and have poorer risk profiles than their 
male counterparts. This has resulted in the 
exclusion of women from participation in 
past clinical trials, reducing their power to 
detect differences in outcomes between the 
two sexes.23 In recent years, the recruitment 
of female patients in clinical trials has 
increased, shedding more light on the 
clinical outcomes of the different therapeutic 
strategies in males and females. 
Medical management
Women with an AMI are more likely to 
develop complications such as bleeding, 
cardiogenic shock, heart failure, stroke and 
re-infarction.1   The medical management 
of AMI often includes thrombolysis (in 
the setting of ST-elevation MI), heparin, 
anti-platelet therapy, beta-blockers, statins 
and ACE-inhibitors.  Data on thrombolysis 
and gender differences is somewhat 
contradictory.24 In the International Tissue 
Plasminogen Activator /Streptokinase 
Mortality study, mortality was found to be 
similar in both sexes with women however 
having a higher rate of haemorrhagic stroke. 
25   Females are more likely to achieve a 
higher activated thromboplastin time after 
administration of unfractionated heparin.26   
A greater reduction in mortality rate and 
myocardial infarction was seen in females 
after administration of dalteparin as 
compared to males.27 Similarly in the TIMI 
and the ESSENCE trials, a significant benefit 
of enoxaparin over unfractionated heparin 
was seen in women but not in men.28 No sex-
related differences were seen in trials with 
bivalirudin 29 and fondaparinux. 30
A metanalysis of randomized trials has 
shown that glycoprotein IIb/IIIa receptor 
antagonists gave a significant increased 
bleeding risk in women. 31 However, if the 
baseline troponin levels were high, then 
beneficial effects were seen in both sexes.32 
There were no sex differences in the response 
to aspirin, ticlopidine, clopidogrel and 
prasugrel.33, 34    A more pronounced decrease 
in heart rate and blood pressure was seen in 
women on beta-blockers and ACE-inhibitors 
compared to men.35
Coronary revascularization
Women with CAD are often older, obese, 
suffer more from diabetes and hypertension, 
generally smoke, may have had a previous 
cardiac event and surgical revascularization, 
and usually have a smaller reference diameter 
of the target vessel as well as a lower Syntax 
Score compared to men. Earlier studies during 
the balloon angioplasty era reported a lower 
procedural success, a higher in-hospital 
mortality and unfavourable long term clinical 
outcomes among women. 36   The unrestricted 
use of drug eluting stents (DES) in more 
recent years, is now associated with similar 
long-term safety and efficacy among women 
and men with CAD.  The similar outcomes in 
terms of cardiac death, myocardial infarction 
and stent thrombosis are reassuring and 
reinforce the lack of sex difference in terms of 
patient outcome and device safety. 37 
Generally women have a higher mortality 
risk after coronary artery bypass graft (CABG) 
than men. In fact, in-hospital mortality after 
CABG has been shown to be twice as high 
in women as compared to men.38 The more 
advanced age, smaller body size, smaller 
coronary lumen, and higher incidence of 
comorbidities all contribute to this. Women 
have a more difficult recovery period after 
CABG.39 On the other hand, The Bypass 
Angioplasty Revascularisation Investigation 
(BARI) group observed no gender differences 
in early or late mortality after percutaneous 
transluminal angioplasty (PTCA) and CABG. 40
Conclusion
This review gives insight to the complexity 
in the pathophysiology, assessment and 
management of CAD in women. The inclusion 
of more female patients in clinical trials, will 
definitely shed more light on the extent of 
gender differences in CAD. Future research 
may help clarify the intricate effects of 
oestrogen on the human heart.
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Key points
•	 IHD is the leading cause of death in the female population. 
•	 The cardioprotective mechanism of oestrogen is still unclear. 
•	 Female patients with CAD are often older and have multiple co-morbidities. 
•	 Exercise stress testing should be performed in females with moderate pre-test 
probability of IHD.
•	 Further clinical trials are needed to clarify how best to treat female patients with CAD. 
